Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous

Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT07360132 by Shanghai Huaota Biopharmaceutical Co., Ltd., with a registry enrolment figure of 480 participants, started 2026-01-15 and due to reach its primary completion in 2028-04-10. Interventions recorded: Carboplatin Injection; Paclitaxel Injection. Conditions listed: Squamous Non-small Cell Lung Cancer. Primary outcome: Progression-free survival (PFS). Lung eligibility wording from the registry: "Histologically or cytologically confirmed locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) (confirmed per the 9th Edition of the TNM Staging System for Lung Cancer by the Union for International Cancer Control \[UICC\] and the American Joint Committee on". Sites: China. No results are recorded here; the registry entry is the source.